XRP44X

Discontinued Product

XRP44X (Cat. No. 3101) has been withdrawn from sale for commercial reasons.
Cat.No. 3101 - XRP44X | C21H21ClN4O | CAS No. 729605-21-4
Description: Ras-Net (Elk-3) pathway inhibitor; also microtubule depolymerization agent and angiogenesis inhibitor
Chemical Name: 1-(3-Chlorophenyl)-4-[(3-methyl-1-phenyl-1H-pyrazol-5-yl)carbonyl]piperazine
Purity: ≥99% (HPLC)
Datasheet
Citations
Reviews
Literature

Biological Activity

Ras-Net (Elk-3) pathway inhibitor (IC50 = 10 - 20 nM). Indirectly inhibits Net phosphorylation upstream of Erk1/2 activation. Mediates G2-M cell cycle arrest, suppresses growth of multiple cell types (IC50 ~ 2 nM), inhibits angiogenesis and acts as a microtubule depolymerizing agent in vitro.

Technical Data

M. Wt 380.87
Formula C21H21ClN4O
Storage Store at RT
Purity ≥99% (HPLC)
CAS Number 729605-21-4
PubChem ID 10339779
InChI Key NPHPNBGYPKBDDB-UHFFFAOYSA-N
Smiles CC1=NN(C2=CC=CC=C2)C(C(N3CCN(C4=CC(Cl)=CC=C4)CC3)=O)=C1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

References

References are publications that support the biological activity of the product.

Wasylyk et al (2008) Inhibition of the Ras-Net (Elk-3) pathway by a novel pyrazole that affects microtubules. Cancer Res. 68 1275 PMID: 18316589

View Related Products by Product Action

View all Ras GTPase Inhibitors

Keywords: XRP44X, XRP44X supplier, Ras-Net, pathway, inhibitors, inhibits, Antiangiogenics, microtubule, depolymerization, depolymerisation, agent, MAPK, Signaling, Signalling, G, Proteins, Small, Mitogen-Activated, Protein, Kinases, Tau, Tubulin, Microtubules, Other, Mitosis, Ras, GTPases, 3101, Tocris Bioscience

Citations for XRP44X

Citations are publications that use Tocris products.

Currently there are no citations for XRP44X.

Reviews for XRP44X

There are currently no reviews for this product. Be the first to review XRP44X and earn rewards!

Have you used XRP44X?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Cancer

Cancer Research Product Guide

A collection of over 750 products for cancer research, the guide includes research tools for the study of:

  • Cancer Metabolism
  • Epigenetics in Cancer
  • Receptor Signaling
  • Cell Cycle and DNA Damage Repair
  • Angiogenesis
  • Invasion and Metastasis
RAS Oncoproteins

RAS Oncoproteins Scientific Review

Written by Kirsten L. Bryant, Adrienne D. Cox and Channing J. Der, this review provides a comprehensive overview of RAS protein function and RAS mutations in cancer. Key signaling pathways are highlighted and therapeutic vulnerabilities are explored. This review also includes a detailed section on RAS drug discovery and targeting synthetic lethal interactors of mutant RAS. Compounds available from Tocris are listed.

Cell Cycle & DNA Damage Repair

Cell Cycle & DNA Damage Repair Poster

In normal cells, each stage of the cell cycle is tightly regulated, however in cancer cells many genes and proteins that are involved in the regulation of the cell cycle are mutated or over expressed. Adapted from the 2015 Cancer Product Guide, Edition 3, this poster summarizes the stages of the cell cycle and DNA repair. It also highlights strategies for enhancing replicative stress in cancer cells to force mitotic catastrophe and cell death.

Epigenetics in Cancer

Epigenetics in Cancer Poster

Adapted from the 2015 Cancer Product Guide Edition 3, this poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.